Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...